Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J8JP
|
|||
| Former ID |
DCL000930
|
|||
| Drug Name |
Pimavanserin
|
|||
| Synonyms |
ST51054136; AC-5273; I14-1981; 1-[(4-fluorophenyl)methyl]-1-(1-methyl-4-piperidyl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0] | Approved | [1] | |
| Company |
Acadia Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H34FN3O2
|
|||
| Canonical SMILES |
CC(C)COC1=CC=C(C=C1)CNC(=O)N(CC2=CC=C(C=C2)F)C3CCN(CC3)C
|
|||
| InChI |
1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
|
|||
| InChIKey |
RKEWSXXUOLRFBX-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 706779-91-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15056570, 22487415, 44188211, 78486719, 85246183, 92721414, 118844935, 125356530, 126619173, 126661719, 131324331, 134222314, 134339374, 135262066, 135263922, 137005043, 137354663, 152042012, 162104969, 162205223, 163242432, 163884831, 172914648, 174539041, 187072850, 198956315, 210275101, 210280740, 223435110, 223679488, 224220742, 226970761, 241139662, 242550037, 248856106, 249870692, 252166633, 252216077, 252448725
|
|||
| ChEBI ID |
CHEBI:133017
|
|||
| ADReCS Drug ID | BADD_D02451 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2A receptor (HTR2A) | Target Info | Modulator | [1], [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | |||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.